Polymix - Eye Ointment Bacitracin Zinc + Polymixin B Eye prep - 1 3gm tube(s) / 3gm tube OSL Pharma Limited Indication: Bacterial ocular infections Adult Dose: Adult: Ophth Ocular infections; Prevention of ocular infection following surgical procedure: Apply ½ inch 3-4 hrly for acute infections or 2-3 times/day for mild-to-moderate infections for 7-10 days. Treatment should be continued for another 2 days after the eye has apparently recovered. Child Dose: Child: Apply ½ inch ribbon in the affected eye(s) every 3-4 hr for acute infections or 2-3 times/day for mild-to-moderate infections for 7-10 days. Treatment should be continued for another 2 days after the eye has apparently recovered. Contraindication: Hypersensitivity. Mode of Action: Bacitracin, inhibits bacterial cell wall synthesis and is active against many gram-positive bacteria (e.g. staphylococci, streptococci, corynebacteria and clostridia) and some gram-negative species (e.g. Neisseria and Haemophilus influenzae). They are often found in combinations in topical preparations as broad spectrum antibacterial agents. Polymyxin B disrupts the bacterial cytoplasmic membrane of mostly gm-ve organisms allowing leakage of intracellular constituents by binding to membrane phospholipids. Precaution: Ointment may blur vision. Prolonged use of the antibacterial preparation may cause overgrowth of non-susceptible organisms, including fungi. Pregnancy and lactation. Lactation: Excretion in breast milk unknown; use caution Side Effect: <1% Allergic contact dermatitis,Conjunctival erythema,Swelling,Itching,Burning Pregnancy Category Note: Pregnancy Category: C Lactation: unknown if distributed in breast milk Interaction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents. Polymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).